- Report
- April 2025
- 200 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- April 2025
- 200 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- February 2025
- 200 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- June 2025
- 400 Pages
Global
From €4390EUR$4,949USD£3,812GBP
- Report
- July 2025
- 275 Pages
Global
From €4431EUR$4,995USD£3,847GBP
- Report
- May 2025
- 90 Pages
Global
From €3500EUR$4,227USD£3,145GBP
- Report
- April 2025
- 125 Pages
Global
From €3657EUR$4,123USD£3,175GBP
€4302EUR$4,850USD£3,735GBP
- Report
- February 2025
- 130 Pages
Global
From €3657EUR$4,123USD£3,175GBP
€4302EUR$4,850USD£3,735GBP
- Report
- November 2022
- 150 Pages
Global
From €5278EUR$5,950USD£4,582GBP
- Report
- October 2022
- 150 Pages
Global
From €5278EUR$5,950USD£4,582GBP
- Report
- August 2024
- 180 Pages
Global
From €3992EUR$4,500USD£3,466GBP
- Report
- August 2023
- 79 Pages
Canada
From €3105EUR$3,500USD£2,696GBP
- Report
- July 2024
- 150 Pages
Global
From €3326EUR$3,750USD£2,888GBP
- Report
- July 2024
- 150 Pages
Global
From €3326EUR$3,750USD£2,888GBP
- Report
- May 2024
- 200 Pages
Global
From €3681EUR$4,150USD£3,196GBP
- Report
- January 2024
- 200 Pages
Global
From €3681EUR$4,150USD£3,196GBP
- Report
- January 2024
- 200 Pages
Global
From €3681EUR$4,150USD£3,196GBP
- Report
- April 2023
- 117 Pages
Global
From €4213EUR$4,750USD£3,658GBP
- Report
- October 2023
- 133 Pages
North America
From €3060EUR$3,450USD£2,657GBP
- Report
- October 2023
- 125 Pages
Africa, Middle East
From €3060EUR$3,450USD£2,657GBP

The Left Atrial Appendage Closure Device (LAACD) is a medical device used to reduce the risk of stroke in patients with atrial fibrillation. It is a minimally invasive procedure that involves the placement of a device in the left atrial appendage, a small pouch in the heart, to prevent blood clots from forming and entering the bloodstream. The device is designed to reduce the risk of stroke without the need for long-term anticoagulation therapy.
The LAACD market is a rapidly growing segment of the cardiovascular device market. It is estimated that the LAACD market will continue to grow due to the increasing prevalence of atrial fibrillation and the need for stroke prevention. The market is expected to benefit from technological advancements, such as the development of new devices and improved delivery systems.
Some of the major players in the LAACD market include Abbott, Boston Scientific, Medtronic, and St. Jude Medical. These companies are actively developing and marketing LAACD devices to meet the needs of patients with atrial fibrillation. Show Less Read more